Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP ‐HF registry

ConclusionsWe found that, after initiation of sacubitril/valsartan, only worse baseline health status was associated with very large health status improvement. Accordingly, a trial of therapy —particularly in those with worse symptoms, function, and quality of life—and assessing treatment response are likely to be the best prospective strategy.

Source: ESC Heart Failure - November 10, 2020 Category: Cardiology Authors: Yevgeniy Khariton, Gregg C. Fonarow, Ann Hellkamp, Laine Thomas, Michael E. Nassif, Javed Butler, Carol I. Duffy, Nancy M. Albert, John A. Spertus Tags: Short Communication Source Type: research